

NCT ID	NCT03577665
Title	Curative Proton Beam Therapy for Patients With Liver Metastasis of Colorectal Cancer
Phase	Not Applicable
Date Added	2018-07-05
Location	Korea, Republic of
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03860272
Title	Fc-Engineered Anti-CTLA-4 Monoclonal Antibody Botensilimab in Advanced Cancer
Phase	Phase 1
Date Added	2019-03-01
Location	Arizona, United States California, United States Colorado, United States Connecticut, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Texas, United States United Kingdom
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Balstilimab, Botensilimab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05973487
Title	A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
Phase	Phase 1
Date Added	2023-08-03
Location	Arizona, United States California, United States Connecticut, United States Florida, United States Illinois, United States Kentucky, United States Michigan, United States Minnesota, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	

Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05976906
Title	Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors
Phase	Phase 1
Date Added	2023-08-04
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05783089
Title	MSLN-targeted CAR-T Cells in Solid Tumors.
Phase	Phase 1
Date Added	2023-03-24
Location	
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Not yet recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05785325
Title	RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer
Phase	Phase 2
Date Added	2023-03-27
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	RC48-ADC plus Bevacizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05798533
Title	Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
Phase	Phase 1
Date Added	2023-04-04
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Cyclophosphamide, Fludarabine, Interleukin-2
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05799443
Title	Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Phase	Phase 2
Date Added	2023-04-05

Location	
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Not yet recruiting
Drugs	cetuximab, Irinotecan Hydrochloride, Tislelizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT00001823
Title	Evaluation for NCI Surgery Branch Immunotherapy Clinical Research Protocols
Phase	
Date Added	1999-11-04
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05382741
Title	Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
Phase	Phase 2
Date Added	2022-05-19
Location	Italy
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Durvalumab Injection for intravenous use 500 mg vial solution for infusion, Regorafenib 30 mg capsules, Imfinzi, Stivarga
Tags	MSS/ MMRp